(E)-3-(2-amino-5-fluorophenyl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(2-amino-5-fluorophenyl)prop-2-enoic acid
• 化学式: C₉H₈FNO₂
• 分子量: 181.16
• InChiKey: JNWFQRBMZKWDLC-DAFODLJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160264518A1

  公开（公告）日：2016-09-15

  The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

  本发明涉及组蛋白去乙酰化酶抑制剂，特别是HDAC8，用于治疗癌症和其他疾病和疾病，以及所述抑制剂的合成和应用。
• ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS
  申请人：RaQualia Pharma Inc.

  公开号：US20150322052A1

  公开（公告）日：2015-11-12

  The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blocker such as Na V1.3 and Na V1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

  本发明涉及式（I）的芳基取代羧酰胺衍生物或其药学上可接受的盐，其具有T型钙通道或电压门控钠通道的阻滞活性，如NaV1.3和NaV1.7，可用于治疗或预防涉及T型钙通道或电压门控钠通道的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及T型钙通道或电压门控钠通道的疾病中使用这些化合物和组合物。
• Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
  申请人：FORMA Therapeutics, Inc.

  公开号：US10266487B2

  公开（公告）日：2019-04-23

  The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

  本发明涉及组蛋白去乙酰化酶（尤其是 HDAC8）的抑制剂，可用于治疗癌症及其他疾病和失调，还涉及上述抑制剂的合成和应用。
• HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2752410B1

  公开（公告）日：2016-08-31
• US20140275074A1
  申请人：——

  公开号：US20140275074A1

  公开（公告）日：2014-09-18